Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma

European Journal of Cancer

Volumn 51, Issue 7, 2015, Pages 833-840

  Schadendorf, Dirk ^a   Amonkar, Mayur M ^b   Stroyakovskiy, Daniil ^c   Levchenko, Evgeny ^d   Gogas, Helen ^e   De Braud, Filippo ^f   Grob, Jean Jacques ^g   Bondarenko, Igor ^h   Garbe, Claus ⁱ   Lebbe, Celeste ^j   Larkin, James ^k   Chiarion Sileni, Vanna ^l   Millward, Michael ^m   Arance, Ana ⁿ   Mandalà, Mario ^o   Flaherty, Keith T ^p   Nathan, Paul ^q   Ribas, Antoni ^r   Robert, Caroline ^s   Casey, Michelle ^b   Demarini, Douglas J ^b   Irani, Jhangir G ^b   Aktan, Gursel ^b   Long, Georgina V ^t   more..

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b GLAXOSMITHKLINE   (United States)

^c Moscow Municipal Oncology Hospital #62   (Russian Federation)

^d N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^e UNIVERSITY OF ATHENS   (Greece)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g HÔPITAL SAINTE MARGUERITE   (France)

^h Dnipropetrovsk State Medical Academy   (Ukraine)

ⁱ UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^j SAINT LOUIS HOSPITAL   (France)

^k ROYAL MARSDEN HOSPITAL   (United Kingdom)

^l VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^m SIR CHARLES GAIRDNER HOSPITAL   (Australia)

ⁿ HOSPITAL CLÍNIC   (Spain)

^o PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^p MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^q MOUNT VERNON CANCER CENTRE   (United Kingdom)

^r UNIVERSITY OF CALIFORNIA   (United States)

^s INSTITUT GUSTAVE ROUSSY   (France)

^t UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

B raf; Dabrafenib; Melanoma; Molecular targeted; Protein kinase inhibitors; Proto oncogene proteins; therapy; Trametinib

Indexed keywords

B RAF KINASE; DABRAFENIB; TRAMETINIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; OXIME; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE; VALINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PAIN; COGNITION; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EMOTION; FATIGUE; FOLLOW UP; FUNCTIONAL STATUS; GENE MUTATION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NAUSEA AND VOMITING; PAIN ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SOCIAL INTERACTION; AMINO ACID SUBSTITUTION; CLINICAL TRIAL; GENETICS; HEALTH STATUS; MELANOMA; METASTASIS; MULTICENTER STUDY; PAIN MEASUREMENT; PATHOLOGY; SKIN NEOPLASMS;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HEALTH STATUS; HUMANS; IMIDAZOLES; MELANOMA; NEOPLASM METASTASIS; OXIMES; PAIN MEASUREMENT; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES; QUALITY OF LIFE; SKIN NEOPLASMS; VALINE;

EID: 84927513281     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.03.004     Document Type: Article

References (26)

1. F.S. Hodi, S.J. O'Day, and D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 8 2010 711 723
2. C. Robert, L. Thomas, and I. Bondarenko Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 26 2011 2517 2526
3. C. Robert, A. Ribas, and J.D. Wolchok Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial Lancet 384 9948 2014 1109 1117
4. P.B. Chapman, A. Hauschild, and C. Robert Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 26 2011 2507 2516
5. A. Hauschild, J.J. Grob, and L.V. Demidov Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Lancet 380 9839 2012 358 365
6. K.T. Flaherty, C. Robert, and P. Hersey Improved survival with MEK inhibition in BRAF mutated melanoma N Engl J Med 367 2 2012 107 114
7. V.K. Sondak, and L.E. Flaherty Targeted therapies: improved outcomes for patients with metastatic melanoma Nat Rev Clin Oncol 8 9 2011 513 515
8. P.B. Chapman, A. Hauschild, and C. Robert Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma J Clin Oncol 30 Suppl. 2012 [abstract 8502]
9. A. Hauschild, J.J. Grob, and L.V. Demidov An update on BREAK-3, a phase III, randomized trial: dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM) J Clin Oncol 31 Suppl. 2013 [abstract 9013]
10. G.V. Long, D. Stroyakovskiy, and H. Gogas Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma N Engl J Med 371 20 2014 1877 1888
11. C. Robert, B. Karaszewska, and J. Schachter Improved overall survival in melanoma with combined dabrafenib and trametinib N Engl J Med 372 2015 30 39
12. J. Larkin, P.A. Ascierto, and B. Dréno Combined vemurafenib and cobimetinib in BRAF-mutated melanoma N Engl J Med 371 20 2014 1867 1876
13. European Organisation for Research and Treatment of Cancer. EORTC quality of life questionnaire (EORTC QLQ-C30). < http://groups.eortc.be/qol/eortc-qlq-c30 > [accessed December 22, 2014].
14. N.K. Aaronson, S. Ahmedzai, and B. Bergman The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 5 1993 365 376
15. D. Osoba, N. Aaronson, and B. Zee Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. The Study Group on Quality of Life of the EORTC and the Symptom Control and Quality of Life Committees of the NCI of Canada Clinical Trials Group Qual Life Res 6 2 1997 103 108
16. D. Osoba, B. Zee, and J. Pater Psychometric properties and responsiveness of the EORTC quality of life questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer Qual Life Res 3 5 1994 353 364
17. M.J. Hjermstad, S.D. Fossa, and K. Bjordal Test/retest study of the European Organization for Research and Treatment of Cancer core quality-of-life questionnaire J Clin Oncol 13 5 1995 1249 1254
18. S. Kaasa, K. Bjordal, and N. Aaronson The EORTC core quality of life questionnaire (QLQC30): validity and reliability when analysed with patients treated with palliative radiotherapy Eur J Cancer 31A 13-14 1995 2260 2263
19. D. Osoba, G. Rodrigues, and J. Myles Interpreting the significance of changes in healthrelated quality-of-life scores J Clin Oncol 16 1998 139 144
20. Y. Brandberg, S. Aamdal, and L. Bastholt Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b Eur J Cancer 48 13 2012 2012 2019
21. P. Mohr, A. Hauschild, U. Trefzer, and M. Weichenthal Quality of life in patients receiving high-dose interferon alfa-2b after resected high-risk melanoma J Clin Oncol 27 24 2009 e70 [author reply e71]
22. A. Bottomley, C. Coens, and S. Suciu Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group J Clin Oncol 27 18 2009 2916 2923 [Erratum in J Clin Oncol 2009;27(27):4630]
23. S. Kotapati, S. Francis, and B. Sherrill Health related quality of life (HRQL) of patients receiving ipilimumab with dacarbazine as first-line treatment for unresectable stage III/IV melanoma Pigment Cell Melanoma Res 24 2011 1037 [abstract SMRP50]
24. J.J. Grob, M.M. Amonkar, and S. Martin-Algarra Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality of life analyses of the BREAK-3 study comparing dabrafenib with DTIC Ann Oncol 25 7 2014 1428 1436
25. D. Schadendorf, M.M. Milhem, and M. Amonkar Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study Ann Oncol 25 3 2014 700 706
26. N.W. Scott, P.M. Fayers, and N.K. Aaronson EORTC QLQ-C30 reference values 2008 EORTC Publications Brussels, Belgium